Upadacitinib shows strong response rates in tough pediatric IBD cases, but data remain limited to retrospective studies.
Ahmed A. Al Sarkhy, Alhanouf A. AlZahrani and Afnan A. AlSunaidi
Pooling five retrospective studies covering 248 children with refractory inflammatory bowel disease, this meta-analysis found high rates of clinical response and steroid-free remission with upadacitinib after induction, sustained into maintenance therapy for most patients. Serious adverse events, including herpes zoster reactivation, occurred at low but notable rates, with no blood clot events reported. The authors caution that prospective trials are still needed to confirm efficacy and safety in this population.
- The question: Can upadacitinib help children whose bowel disease resists other treatments?
- The study: A meta-analysis pooled five retrospective studies of children treated with upadacitinib.
- The finding: Across 248 children, high rates of clinical response and steroid-free remission followed induction, sustained into maintenance for most patients.
- The nuance: Serious adverse events, including herpes zoster reactivation, were low but notable, and no blood clot events were reported.
Takeaway: promising results, but prospective trials are still needed to confirm efficacy and safety in children.
Narrated (standard AI voice, not a cloned voice) with burned-in captions matching the narration word-for-word — safe to watch muted. Built from this article’s SGA Briefing only.
This links to the publisher’s open-access copy of record. A self-hosted PDF will appear here once one is on file.